Identify serotonin abnormalities causing pain
- Trial ID
- NCT06008704
- Official Title
- Pathophysiology of Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
- Goal
- Identify serotonin abnormalities causing pain
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Toulouse
- Study Type
- INTERVENTIONAL
- Enrollment
- 34 participants
- Conditions
- Parkinson Disease
- Interventions
- Clinical assessment, Pain characteristics assessment, MRI, Thermotest, UPDRS-III Scale, [18F]-MPPF PET scan
Plain-Language Summary
The team is trying to find out whether changes in the brain's serotonin 5-HT1A system help explain chronic central pain in Parkinson's, so we can better understand why some people with PD have persistent, hard-to-treat pain. They use a PET scan with the tracer [18F]-MPPF, which binds to 5-HT1A receptors to map serotonin signaling, along with MRI, sensory thermotesting and pain and motor assessments; scans are done while participants stay on their usual, stable Parkinson medications so results reflect typical treatment. The trial is looking for people aged 40 to 80 with Parkinson's by UKPDSBB criteria, on stable anti-PD meds for at least 4 weeks, good cognition (MoCA >25) and a specified depression score (HADS-D ≥11), and either chronic central pain with average VAS ≥4 or little/no pain (VAS ≤4); people taking drugs that affect 5-HT1A, with MRI contraindications, or with disabling dyskinesias are excluded.
Locations
- Centre Hospitalier Universitaire de Toulouse, Toulouse, Haute-Garonne, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinical assessment. The team is trying to find out whether changes in the brain's serotonin 5-HT1A system help explain chronic central pain in Parkinson's, so we can better understand why some people with PD have persistent, hard-to-treat pain. They use a PET scan with the tracer [18F]-MPPF, which binds to 5-HT1A receptors to map serotonin signaling, along with MRI, sensory thermotesting and pain and motor assessments; scans are done while participants stay on their usual, stable Parkinson medications so results reflect typical treatment. The trial is looking for people aged 40 to 80 with Parkinson's by UKPDSBB criteria, on stable anti-PD meds for at least 4 weeks, good cognition (MoCA >25) and a specified depression score (HADS-D ≥11), and either chronic central pain with average VAS ≥4 or little/no pain (VAS ≤4); people taking drugs that affect 5-HT1A, with MRI contraindications, or with disabling dyskinesias are excluded.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 8 months.